Clinical & Experimental Cardiology
Open Access

Complications in Prognosis and Treatment of Cardiac Amyloidosis

Robert Sebastian^{* *}Correspondence: Robert Sebastian, Department of Medical Surgical Sciences and Biotechnologies, Sapienza University, Latina, Italy, Email:

Author info »

About the Study

The word "amyloidosis" describes a group of illnesses that can affect practically any organ system in the body and are thought to be caused by extracellular proteins that misfold and deposit in tissues. The precursor protein that is overbuilt determines the particular amyloid type. Using Congo-red dye, which exhibits a unique green birefringence under cross-polarized light; this has to be validated histopathologically. Secondary, familial or senile, and light-chain amyloidosis is the three main types that are linked to cardiac problems. The prognosis and probability of cardiac involvement vary depending on the type. Amyloid cardiomyopathy frequently manifests as heart failure, which frequently includes dyspnea, oedema, angina, pre-syncope, and syncope as presenting symptoms.

While cardiac amyloidosis is characterized by wall thickening brought on by interstitial amyloid deposits, the word "hypertrophy" for this type of LV wall thickening is not completely accurate because "hypertrophy" is largely a histological diagnostic and refers to an enlarged size of cardiomyocytes. However, the term "hypertrophy" for cardiac amyloidosis has also become well-established in the literature. Only around 10% of individuals with AL amyloidosis have overt multiple myeloma or, in extremely rare circumstances, a secretory active B-cell lymphoma. Instead, the underlying source of AL amyloidosis is often a tiny clonal B cell or plasma cell population. Lambda lightchain expression may be discovered in around 70% of instances with AL amyloidosis.

The interstitial deposition of the immunoglobulin light chains as well as their inherent toxicity is both responsible for the cardiac dysfunction seen in AL amyloidosis. Myocytes may experience lysosomal dysfunction, oxidative stress, apoptosis, and deregulation of MAP kinase signaling transduction pathways and autophagy when exposed to amyloidogenic free light chains. These results imply that the fast disease development and poor prognosis are at least largely due to direct intracellular cytotoxic actions of immunoglobulin light chains.

Cardiomyloidosis is extremely difficult to diagnose and is frequently misdiagnosed. Tissue biopsy is required for confirmation of the diagnosis, even if imaging tests (such as echocardiography and cardiovascular magnetic resonance) may serve as guidance. The first step in treating cardiac amyloidosis is to address the underlying heart failure.

Patients with any conduction issues often need to have pacemakers implanted. The next stage in deteriorating heart failure is transplantation. However, the goal of all amyloidosis therapy, regardless of kind, is to stop further amyloid deposition while controlling concomitant symptoms. Light chain amyloidosis is a clonal plasma cell proliferative condition that results in the deposition of misfolded immunoglobulin light chains as amyloid fibrils in a variety of organs, including the heart in nearly half of cases. Extracellular infiltration of the myocardium causes cardiac dysfunction in AL amyloidosis, but there is frequently evidence of a cardiotoxic impact induced by pre-fibrillar light chain aggregates as well. The main predictor of morbidity and death is the degree of heart dysfunction.

The kind of cardiac amyloidosis that is most frequently diagnosed is light chain amyloidosis. One or more essential organ systems, most frequently the liver, peripheral and autonomic nerve systems, and soft tissues, may be affected. In some cases, the heart is the sole clinically implicated organ and is commonly afflicted. Clinical manifestation reflects the variable multisystem amyloid deposition. Examination symptoms such as macroglossia, periorbital pupura, submandibular gland enlargement, and nail dystrophy may indicate soft tissue and small vessel amyloid infiltration. Loss of weight and fatigue are frequent. Palpable organomegaly may be brought on by hepatic or splenic invasion. The most typical symptom of renal failure is nephrotic range proteinuria. The diagnosis of early cardiac amyloidosis is quite difficult.

It's possible that the traditional signs of "right-sided" congestive heart failure won't show up until the heart disease is quite advanced. Patients who have already begun taking diuretics may not exhibit any signs of peripheral oedema, hepatomegaly, elevated jugular venous pressure, a third heart sound, or any of these conditions. A "glove and stocking" distribution of paraesthesia or dysesthesia characterizes peripheral neuropathy, which is quite prevalent. Orthostatic hypotension, alternating diarrhoea and constipation, and erectile dysfunction are all signs of autonomic neuropathy, which is a crucial diagnostic indicator.

At least 95% of individuals can have the monoclonal immunoglobulin or free light chains detected in their serum and/or urine utilizing sensitive tests, while standard serum electrophoresis frequently misses these substances. The lack of a detectable clone makes it difficult to make a diagnosis and track a patient's response to treatment. Diagnostic and therapeutic challenges exist with cardiac amyloidosis. Early diagnosis is being made possible by increased awareness and advancements in CMR and DPD scintigraphy. Treatment for AL amyloidosis has evolved remarkably, but the outlook for the 40% of patients who initially have extensive cardiac involvement is still grim. There are many cutting-edge targeted therapies in development that have the potential to stop the development of new amyloid and enhance the clearance of existing amyloids.